The FINANCIAL -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced on November 3 the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets.

Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.

As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity in the U.S.

Teva is distributing the product, under a license agreement entered into between Teva's subsidiary Barr Pharmaceuticals, Inc. and sanofi-aventis U.S. Allegra-D is a registered trademark of sanofi-aventis U.S.

Related Stories

• Ticagrelor (BRILINTA) demonstrated greater efficacy over clopidogrel in the most urgent clinical set
• Merck Expresses Confidence in the Efficacy and Safety Profiles of ZETIA (ezetimibe) and VYTORIN
• GSK and Nabi announce agreement for NicVAX, a vaccine for nicotine addiction